LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

Search

Ligand Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

194.64 -3.63

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

193.84

Max

199.02

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-72M

45M

Pardavimai

-56M

60M

P/E

Sektoriaus vid.

32.685

57.05

Pelno marža

75.058

Darbuotojai

47

EBITDA

-83M

66M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+22.81% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-05-07

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

381M

4B

Ankstesnė atidarymo kaina

198.27

Ankstesnė uždarymo kaina

194.64

Naujienos nuotaikos

By Acuity

50%

50%

158 / 349 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Ligand Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-27 17:33; UTC

Svarbiausios naujienos

ECB Should Not Rush Its Response to Iran Conflict, Says Schnabel -- Update

2026-03-27 17:00; UTC

Svarbiausios naujienos

ECB Shouldn't Rush Its Response to Iran Conflict, Schnabel Says

2026-03-27 16:03; UTC

Svarbiausios naujienos

Fertilizer Maker Yara Warns Farmers Are Being Squeezed by Price Surge Amid War -- Commodities Roundup

2026-03-27 14:50; UTC

Pagrindinės rinkos jėgos

Cybersecurity Stocks Fall on Leak About New Claude Model's Cyber Capabilities

2026-03-27 14:37; UTC

Įsigijimai, susijungimai, perėmimai

Nestle's Water Business Stake Sale Could Value Unit at Around $5.76 billion, FT Says, Citing Sources

2026-03-27 14:29; UTC

Svarbiausios naujienos

EU Finance Ministers Tally Economic Hit of Iran War -- Update

2026-03-27 14:16; UTC

Svarbiausios naujienos

The Week in Oil: Mixed Signals Over U.S.-Iran Talks Keep Traders Wary

2026-03-27 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-03-27 19:16; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Oil Futures Rise On Uncertainty Ahead of Weekend -- Market Talk

2026-03-27 19:07; UTC

Rinkos pokalbiai

U.S. Natural Gas Gains As April Contract Expires -- Market Talk

2026-03-27 19:04; UTC

Rinkos pokalbiai

Gold Rises But Can't Finish the Week Positive -- Market Talk

2026-03-27 19:03; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Global Forex and Fixed Income Roundup: Market Talk

2026-03-27 19:02; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Among Central Banks, Canada Has Room to Handle Oil Inflation -- Market Talk

2026-03-27 18:12; UTC

Rinkos pokalbiai

Foreign Fuels and Feedstocks to Get RINs Until 2028 -- Market Talk

2026-03-27 17:36; UTC

Svarbiausios naujienos

The Iran War and Oil Prices Bring Risk of Deeper Market Lows. There Are Echoes of 2008. -- Barrons.com

2026-03-27 17:34; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Delivery Hero Shares Bounce as Stake-Sale Report Whets Investor Appetites -- Market Talk

2026-03-27 17:29; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Falls By 5 to 409 -- Market Talk

2026-03-27 16:38; UTC

Rinkos pokalbiai

Carnival's Outlook Assumes Oil Prices Will Come Down -- Market Talk

2026-03-27 16:32; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Chinese Exposure to Higher Energy Costs Seen as Limited -- Market Talk

2026-03-27 16:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-03-27 15:43; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Hormuz Closure Sends Tanker Rates to Record Highs -- Market Talk

2026-03-27 15:25; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-27 15:25; UTC

Rinkos pokalbiai

Swiss Franc Dented by Rising European Yields, SNB Intervention Threats -- Market Talk

2026-03-27 15:00; UTC

Svarbiausios naujienos

Fed's Barkin: Inflation Progress 'May Be at Risk of Stalling'

2026-03-27 15:00; UTC

Svarbiausios naujienos

Fed's Barkin: Holding Rates Steady in March 'Felt Prudent'

2026-03-27 15:00; UTC

Svarbiausios naujienos

Fed's Barkin Says Iran War Raising Economic Uncertainty

2026-03-27 14:36; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Rising Yields, Oil Prices Seen as Overreaction -- Market Talk

2026-03-27 14:26; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Treasury Yields Mixed as Iran Peace Deal Remains Elusive -- Market Talk

2026-03-27 14:14; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-27 14:14; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Ligand Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

22.81% į viršų

12 mėnesių prognozė

Vidutinis 250.17 USD  22.81%

Aukščiausias 277 USD

Žemiausias 230 USD

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ligand Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

7 ratings

7

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

102.5 / 109.24Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Very Strong Bearish Evidence

Ilgalaikis periodas

Weak Bullish Evidence

Rinkos nuotaikos

By Acuity

158 / 349 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.
help-icon Live chat